Lim James C
Known title: Executive Vice PresidentCIK: 0001551804
Associated companies
Transaction History
| BDX | ▲ Buy | Grant | 3,280 | $0 | 6/17/2022 | View on chart |
| BDX | ▲ Buy | Grant | 893 | $0 | 11/26/2021 | View on chart |
| BDX | ▲ Buy | Option Exercise | 14,584 | $2.0M | 9/3/2021 | View on chart |
| BDX | ▼ Sell | Other | 7,628 | $2.0M | 9/3/2021 | View on chart |
| BDX | ▼ Sell | Open Market | 6,956 | $1.8M | 9/3/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
BDX Revello Stent Trial Success, Revenue Up 5.4%, Earnings Down 34%
The company announced that its Revello stent achieved strong results in the AGILITY trial for peripheral artery disease patients. Revenue rose 5.4% year‑over‑year, but net earnings fell 34.3%, reflecting higher costs or lower margins. The dividend yield sits at 1.59% and analysts see a target of $194, while the stock trades near the top of its 52‑week range.
BDX Revello Stent Trial Success, Revenue Up 5.4%, Earnings Down 34%. The company announced that its Revello stent achieved strong results in the AGILITY trial for peripheral artery disease patients. Revenue rose 5.4% year‑over‑year, but net earnings fell 34.3%, reflecting higher costs or lower margins. The dividend yield sits at 1.59% and analysts see a target of $194, while the stock trades near the top of its 52‑week range.